Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor

Evaluating stereotactic ablative body radiotherapy treatment option for low volume advanced prostate cancer

Posted by on Nov 10, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of stereotactic ablative body radiotherapy (SABR) used as a treatment in low volume metastatic (spread) prostate cancer. This study found that SABR is effective and has few side-effects. Some background Stereotactic ablative body radiotherapy (SABR) is a treatment option...

Read More

Evaluating cabazitaxel in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 6, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effectiveness of cabazitaxel used for patients with metastatic castration-resistant prostate cancer. This study found that patients treated with cabazitaxel had maintained or improved quality of life and pain control. Some background One treatment option for prostate cancer is androgen deprivation...

Read More

Outcomes of palliative resections of the prostate in patients with locally advanced prostate cancer

Posted by on Jul 24, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the usefulness of transurethral resection of the prostate (TURP). This study found that TURP is a surgical option to relieve bladder obstruction in patients with locally advanced prostate cancer. Some background Advanced prostate cancer may cause significant complications which affect...

Read More

Does age matter? Enzalutamide or bicalutamide for mestastatic castration-resistant prostate cancer patients of different ages

Posted by on Feb 12, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...

Read More

Can the neutrophil to lymphocyte ratio predict outcome in enzalutamide-treated prostate cancer patients?

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide.  Some background Treatment for metastatic...

Read More